The June 2026 quarter results underscore the seasonal strength of the agrochemical business, with the company capitalising on peak application season across its product portfolio. Year-on-year comparison shows consolidated net profit advancing 20.46% from ₹178.34 crores in Q1 FY26, demonstrating sustained growth momentum despite a challenging base quarter. The sequential improvement is particularly noteworthy, reflecting strong execution during the critical Kharif season.
Financial Performance: Margin Expansion Drives Profitability
Sumitomo Chemical India's Q1 FY27 revenue stood at ₹1,063.35 crores, registering a modest 0.62% year-on-year growth but a robust 55.52% sequential increase from ₹683.74 crores in Q4 FY26. This pronounced sequential uptick reflects the typical seasonality pattern in the agrochemical sector, where the first quarter coincides with peak Kharif sowing season across India. The company's ability to maintain revenue levels despite marginal YoY growth in a competitive landscape demonstrates market share resilience.
| Quarter | Net Sales (₹ Cr) | QoQ % | Net Profit (₹ Cr) | QoQ % | OPM % |
|---|---|---|---|---|---|
| Jun'26 | 1,063.35 | +55.52% | 214.83 | +93.14% | 21.94% |
| Mar'26 | 683.74 | +20.38% | 111.23 | +47.07% | 19.62% |
| Dec'25 | 567.98 | -38.92% | 75.63 | -57.46% | 17.52% |
| Sep'25 | 929.82 | -12.01% | 177.77 | -0.32% | 23.45% |
| Jun'25 | 1,056.78 | +55.54% | 178.34 | +79.09% | 20.74% |
| Mar'25 | 679.42 | +5.84% | 99.58 | +14.53% | 17.60% |
| Dec'24 | 641.92 | — | 86.95 | — | 16.53% |
The standout feature of Q1 FY27 was exceptional margin expansion across all profitability metrics. Operating profit before depreciation, interest, and tax (excluding other income) surged to ₹233.29 crores, representing a 21.94% margin – the highest in seven quarters. This 232 basis point sequential improvement from 19.62% reflects favourable product mix, better pricing realisation, and operational efficiency gains. PAT margin reached an impressive 20.17%, up from 16.28% in the previous quarter, highlighting strong operating leverage and effective cost management.
Employee costs increased modestly to ₹73.22 crores from ₹68.04 crores, representing a manageable 7.61% sequential rise despite the sharp revenue uptick. This demonstrates improving productivity metrics and effective workforce utilisation. Other income contributed ₹47.28 crores during the quarter, up from ₹32.17 crores sequentially, primarily reflecting treasury income on the company's substantial cash reserves. The tax rate remained stable at 25.58%, marginally higher than the previous quarter's 24.55%, indicating normalised tax provisions.
Operational Excellence: Capital Efficiency Drives Returns
Sumitomo Chemical India's operational metrics reveal a company operating at peak efficiency. The company's return on equity (ROE) stands at a robust 18.40% on an average basis, reflecting superior capital allocation and profitability generation. This positions the company favourably within the agrochemical sector, where sustained ROE above 15% indicates quality management and competitive advantages. The latest ROE of 16.37% remains healthy, though marginally below the average, suggesting some normalisation from exceptional prior periods.
Capital Efficiency Highlights
Return on Capital Employed (ROCE): 31.12% (average) demonstrates exceptional capital productivity, with the company generating ₹31 of operating profit for every ₹100 of capital deployed. This significantly outpaces the cost of capital, creating substantial value for shareholders. The latest ROCE of 24.73%, whilst lower than the average, still represents excellent capital efficiency.
Debt-Free Balance Sheet: With net debt-to-equity at -0.28, Sumitomo Chemical India operates as a net cash company, providing financial flexibility for growth investments, acquisitions, or shareholder returns without leverage constraints.
The balance sheet strength is particularly noteworthy. Shareholder funds expanded to ₹3,389.67 crores in FY26 from ₹2,901.14 crores in FY25, driven by retained earnings and profitability growth. The company maintains minimal long-term debt of just ₹1.33 crores, with current assets of ₹3,340.15 crores comfortably covering current liabilities of ₹969.81 crores, yielding a healthy current ratio of 3.44. Cash and cash equivalents stood at ₹68 crores at FY26-end, supplemented by investments of ₹265.50 crores, providing substantial liquidity cushion.
✓ Key Operational Strengths
Interest Coverage: EBIT-to-interest ratio of 94.29x reflects negligible financial risk and strong earnings quality. The company's operating profit comfortably covers interest obligations nearly 95 times over.
Sales-to-Capital Efficiency: Sales-to-capital employed ratio of 1.26x demonstrates effective asset utilisation, with the company generating ₹1.26 of revenue for every rupee of capital employed.
Working Capital Management: Debtors turnover ratio reached a historic high of 4.40 times in H1, indicating faster collection cycles and improved working capital efficiency.
Fixed assets increased modestly to ₹505.33 crores in FY26, reflecting ongoing capacity enhancement initiatives. The company's disciplined capital expenditure approach – investing ₹331 crores in FY26 whilst generating operating cash flow of ₹445 crores – demonstrates sustainable growth without over-leveraging the balance sheet. This cash flow generation capability provides management with strategic flexibility to pursue organic growth, bolt-on acquisitions, or enhanced shareholder distributions.
Seasonal Dynamics: Navigating Agrochemical Cyclicality
The agrochemical industry exhibits pronounced seasonality, with demand concentrated around the Kharif (monsoon) and Rabi (winter) crop cycles. Sumitomo Chemical India's Q1 performance exemplifies this pattern, with June quarter results typically representing peak seasonal strength. The 55.52% sequential revenue increase from March to June aligns with historical patterns, as farmers intensify crop protection product applications during the crucial monsoon sowing season.
| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 | Change QoQ | Change YoY |
|---|---|---|---|---|---|
| Net Sales (₹ Cr) | 1,063.35 | 683.74 | 1,056.78 | +55.52% | +0.62% |
| EBITDA (₹ Cr) | 233.29 | 134.16 | 219.19 | +73.88% | +6.43% |
| EBITDA Margin % | 21.94% | 19.62% | 20.74% | +232 bps | +120 bps |
| PAT (₹ Cr) | 214.83 | 111.23 | 178.34 | +93.14% | +20.46% |
| PAT Margin % | 20.17% | 16.28% | 16.85% | +389 bps | +332 bps |
The modest 0.62% year-on-year revenue growth warrants closer examination. Whilst sequential performance was exceptional, the muted YoY comparison reflects several industry-wide headwinds: pricing pressures from generic competition, channel inventory destocking in certain segments, and weather-related demand variability in specific geographies. However, the 20.46% YoY profit growth significantly outpacing revenue growth demonstrates the company's pricing power and operational efficiency improvements, with margin expansion more than compensating for volume pressures.
Looking at the broader annual context, FY26 revenues grew 2.9% to ₹3,238 crores, a deceleration from the 10.7% growth in FY25. This moderation reflects industry-wide challenges including erratic monsoon patterns in certain regions, competitive intensity, and price corrections in select molecules. However, profitability metrics remained resilient, with PAT advancing to ₹542 crores in FY26 from ₹506 crores in FY25, driven by margin expansion and cost optimisation initiatives.
Industry Leadership: Competitive Positioning Analysis
| Company | Market Cap (₹ Cr) | P/E (TTM) | P/BV | ROE % | Div Yield % |
|---|---|---|---|---|---|
| Sumitomo Chemical | 26,337 | 47.00 | 7.92 | 18.40 | 0.24 |
| UPL | — | 27.35 | 1.48 | 7.56 | 0.99 |
| PI Industries | — | 33.80 | 3.71 | 15.49 | 0.55 |
| Bayer CropScience | — | 27.64 | 6.42 | 21.04 | 2.95 |
| Sharda Cropchem | — | 11.73 | 2.55 | 13.78 | 1.36 |
| NACL Industries | — | 232.92 | 6.57 | 6.65 | — |
Sumitomo Chemical India's competitive positioning reveals a premium valuation supported by superior profitability metrics. The company's ROE of 18.40% ranks second amongst peers, trailing only Bayer CropScience's 21.04% but significantly ahead of UPL (7.56%), PI Industries (15.49%), and Sharda Cropchem (13.78%). This ROE advantage reflects the company's focus on high-margin specialty products, operational efficiency, and strong brand equity across household insecticides and agricultural pesticides segments.
The price-to-book value of 7.92x represents the highest multiple amongst comparable peers, indicating investor confidence in the company's intangible assets, brand value, and growth prospects. Whilst this premium valuation raises questions about entry points, it's partially justified by the superior ROE and debt-free balance sheet. The P/E ratio of 47.00x, whilst elevated in absolute terms, appears more reasonable when adjusted for quality, sitting between PI Industries (33.80x) and the outlier NACL Industries (232.92x).
Valuation Analysis: Premium Pricing for Quality Franchise
Sumitomo Chemical India trades at a P/E ratio of 47.00x trailing twelve-month earnings, representing a premium to the industry average P/E of 46x. The company's price-to-book value of 7.92x significantly exceeds book value, reflecting market recognition of intangible assets, brand equity, and future earnings potential. The EV/EBITDA multiple of 37.83x and EV/EBIT of 41.98x position the stock at the higher end of agrochemical sector valuations, warranting careful consideration of growth sustainability and margin durability.
The PEG ratio of 18.35 raises concerns about valuation sustainability relative to growth rates. With 5-year sales growth of 4.13% and EBIT growth of 6.55%, the current valuation implies expectations of significant growth acceleration or margin expansion that may prove challenging to achieve. The company's valuation grade of "Very Expensive" reflects these stretched multiples, suggesting limited margin of safety at current price levels of ₹539.40.
However, several factors support the premium valuation: first, the company's debt-free balance sheet and negative net debt-to-equity of -0.28 provide financial flexibility unavailable to leveraged competitors. Second, the superior ROE of 18.40% and ROCE of 31.12% demonstrate sustainable competitive advantages and pricing power. Third, the company's parentage under Sumitomo Chemical Company Limited, Japan provides access to global technology, research capabilities, and product pipeline that justify premium multiples.
Fair Value Assessment
Based on discounted cash flow analysis and peer comparison, the fair value for Sumitomo Chemical India ranges between ₹480-520 per share, suggesting the current price of ₹539.40 embeds optimistic growth assumptions. The stock trades approximately 10-12% above fair value estimates, warranting caution for fresh accumulation at current levels. However, for investors with a 3-5 year horizon willing to pay premium for quality, the company's operational excellence and market leadership justify holding positions.
Shareholding Pattern: Institutional Confidence Building
| Category | Jun'26 | Mar'26 | Dec'25 | QoQ Change |
|---|---|---|---|---|
| Promoter | 75.00% | 75.00% | 75.00% | 0.00% |
| FII | 3.02% | 3.40% | 3.37% | -0.38% |
| Mutual Funds | 7.27% | 6.88% | 6.53% | +0.39% |
| Insurance | 0.82% | 0.98% | 0.95% | -0.16% |
| Other DII | 1.24% | 1.12% | 1.17% | +0.12% |
| Non-Institutional | 12.65% | 12.61% | 12.97% | +0.04% |
Sumitomo Chemical India's shareholding pattern reveals stable promoter commitment at 75.00%, with Sumitomo Chemical Co. Ltd., Japan maintaining consistent stake across quarters. This unwavering promoter holding signals long-term conviction in the Indian agrochemical opportunity and alignment with minority shareholders. The zero pledging of promoter shares further reinforces financial stability and commitment.
Domestic mutual fund holdings increased to 7.27% in June 2026 from 6.88% in March 2026, representing the fourth consecutive quarter of accumulation. This sustained buying by 30 mutual fund houses reflects growing institutional recognition of the company's quality metrics and growth potential. The gradual build-up from 6.16% in June 2025 to current levels demonstrates conviction rather than tactical positioning.
Foreign institutional investor (FII) holdings declined marginally to 3.02% from 3.40%, continuing a gradual reduction trend from 3.65% in September 2025. This modest trimming by 109 FII entities likely reflects profit-booking after the stock's strong performance rather than fundamental concerns. Insurance company holdings also decreased to 0.82% from 0.98%, though the absolute reduction remains small. The combined institutional holding of 12.35% provides adequate liquidity whilst leaving room for further institutional participation.
Stock Performance: Momentum Building After Consolidation
| Period | Stock Return | Sensex Return | Alpha |
|---|---|---|---|
| 1 Day | +3.71% | +1.02% | +2.69% |
| 1 Week | -0.30% | -1.12% | +0.82% |
| 1 Month | +24.00% | -0.34% | +24.34% |
| 3 Month | +21.51% | -0.61% | +22.12% |
| 6 Month | +34.41% | -6.13% | +40.54% |
| YTD | +14.63% | -9.84% | +24.47% |
| 1 Year | -7.64% | -5.68% | -1.96% |
| 2 Years | +6.81% | -5.53% | +12.34% |
| 3 Years | +31.82% | +15.95% | +15.87% |
Sumitomo Chemical India's stock has demonstrated exceptional momentum in recent months, delivering 24.00% returns over the past month and 34.41% over six months, significantly outperforming the Sensex which declined 6.13% over the same period. This 40.54% alpha generation reflects both company-specific positive developments and sector rotation into defensive agrochemical plays amid broader market volatility.
The stock's technical posture has turned decisively bullish, with the trend changing to "Bullish" on July 27, 2026, from "Mildly Bullish" previously. The stock trades above all key moving averages – 5-day (₹532.85), 20-day (₹499.39), 50-day (₹478.85), 100-day (₹447.16), and 200-day (₹454.20) – indicating strong momentum and broad-based buying support. Weekly MACD remains bullish, whilst Bollinger Bands signal continued bullish momentum, suggesting the uptrend has room to extend.
However, the longer-term picture presents a more nuanced view. Over one year, the stock has declined 7.64%, underperforming the Sensex's 5.68% decline and lagging the Pesticides & Agrochemicals sector return of 11.99% by 19.63 percentage points. This underperformance reflects the stock's correction from its 52-week high of ₹665.00, with the current price of ₹539.40 still 18.89% below that peak. The 52-week low of ₹363.30 provides strong support, with the stock now 48.47% above that trough.
The risk-adjusted return profile shows a negative Sharpe ratio over one year, with volatility of 36.69% significantly exceeding the Sensex volatility of 13.54%. This positions the stock in the "HIGH RISK MEDIUM RETURN" category, with a beta of 1.09 indicating higher volatility than the broader market. Delivery volumes have surged 149.36% over the past month, suggesting genuine buying interest rather than speculative activity, though the 1-day delivery of 35.31% remains below the 5-day average of 60.75%.
Investment Thesis: Quality Franchise at Premium Valuation
The investment case for Sumitomo Chemical India rests on four pillars: operational excellence evidenced by superior ROE and ROCE metrics, financial strength with zero debt and robust cash generation, market leadership in select agrochemical segments, and parentage benefits from Sumitomo Chemical Japan's global capabilities. The company's ability to deliver consistent profitability growth even during challenging industry conditions demonstrates resilient business fundamentals and management execution capability.
The current Mojo score of 71/100 with a "BUY" rating reflects this balanced assessment, acknowledging both quality attributes and valuation concerns. The score improvement from "STRONG SELL" territory in early July signals improving sentiment and fundamental momentum. Key strengths supporting the score include high management efficiency with ROE of 18.40%, record quarterly metrics including debtors turnover ratio of 4.40 times, and highest-ever quarterly net sales and operating profit.
Key Strengths & Risk Factors
✓ Key Strengths
- Superior Capital Efficiency: ROE of 18.40% and ROCE of 31.12% significantly exceed industry averages, demonstrating sustainable competitive advantages and pricing power in select product categories.
- Debt-Free Balance Sheet: Net cash position with net debt-to-equity of -0.28 provides financial flexibility for growth investments, acquisitions, or enhanced shareholder returns without leverage constraints.
- Strong Cash Generation: Operating cash flow of ₹445 crores in FY26 comfortably exceeds capital expenditure of ₹331 crores, enabling self-funded growth whilst maintaining dividend distributions.
- Margin Leadership: Operating margin of 21.94% in Q1 FY27 demonstrates pricing power and operational efficiency, with consistent margin expansion trajectory over recent quarters.
- Global Parentage Benefits: Access to Sumitomo Chemical Japan's research capabilities, product pipeline, and technical expertise provides competitive edge in product development and market positioning.
- Working Capital Efficiency: Record debtors turnover ratio of 4.40 times reflects improving collection efficiency and strong customer relationships across distribution channels.
- Stable Promoter Commitment: Unwavering 75% promoter holding with zero pledging signals long-term conviction and alignment with minority shareholder interests.
⚠ Key Concerns
- Premium Valuation: P/E of 47x and P/BV of 7.92x leave limited margin of safety, with PEG ratio of 18.35 suggesting growth expectations may be difficult to meet consistently.
- Modest Growth Trajectory: 5-year sales growth of 4.13% and recent revenue growth of just 0.62% YoY raise questions about volume expansion capabilities in competitive markets.
- Sector Underperformance: 1-year stock return of -7.64% lags the Pesticides & Agrochemicals sector return of 11.99% by nearly 20 percentage points, indicating company-specific challenges.
- High Volatility Profile: Stock volatility of 36.69% significantly exceeds market volatility of 13.54%, with beta of 1.09 indicating amplified downside risk during market corrections.
- Limited Dividend Yield: Dividend yield of just 0.24% with payout ratio of 11.85% provides minimal income component for total return expectations.
- Seasonal Business Cyclicality: Pronounced quarterly volatility driven by agricultural cycles creates earnings unpredictability and working capital management challenges.
- Generic Competition Pressure: Increasing competition from generic agrochemical manufacturers in key product segments could pressure margins and market share over time.
Outlook: Monitoring Points for Investors
Positive Catalysts
- Sustained Margin Expansion: Continuation of operating margin improvement above 21% would validate pricing power and operational efficiency gains.
- Volume Growth Acceleration: Revenue growth exceeding 8-10% on sustained basis would demonstrate market share gains and demand strength.
- New Product Launches: Introduction of differentiated molecules or formulations leveraging parent company technology could drive premium pricing.
- Institutional Accumulation: Continued mutual fund buying and FII re-entry would provide price support and liquidity enhancement.
- Favourable Monsoon Outlook: Normal to above-normal monsoon predictions support strong Kharif and Rabi season demand across product portfolio.
Red Flags to Watch
- Margin Compression: Operating margins falling below 19% would signal pricing pressure or cost inflation challenges requiring attention.
- Market Share Erosion: Consistent revenue growth lagging industry growth rates would indicate competitive positioning weakness.
- Working Capital Deterioration: Debtors turnover declining below 4.0x or inventory days increasing significantly would signal collection or demand issues.
- Valuation De-rating: P/E multiple contracting below 40x could trigger technical selling and momentum reversal despite fundamental stability.
- Institutional Selling: Sustained FII or mutual fund stake reduction exceeding 1% quarterly would raise concerns about institutional conviction.
The Verdict: Quality Play for Patient Investors
Score: 71/100
For Fresh Investors: Sumitomo Chemical India represents a quality agrochemical franchise with superior ROE, debt-free balance sheet, and operational excellence. However, the current valuation at ₹539.40 embeds optimistic growth assumptions with limited margin of safety. Fresh investors should consider accumulating in tranches on dips towards ₹480-500 levels rather than chasing momentum at current prices. The stock suits investors with 3-5 year horizon willing to pay premium for quality and stability.
For Existing Holders: Continue holding positions given strong Q1 FY27 results, improving financial trends, and bullish technical setup. The company's operational metrics justify premium valuation, whilst debt-free balance sheet provides downside protection. Consider partial profit-booking above ₹580-600 levels to manage portfolio risk, but maintain core positions for long-term wealth creation. Set mental stop-loss below ₹480 on closing basis.
Fair Value Estimate: ₹500 per share (7% downside from current levels of ₹539.40)
Sumitomo Chemical India's Q1 FY27 results validate the quality thesis with record profitability and margin expansion, but valuation leaves little room for disappointment. The stock merits inclusion in quality-focused portfolios for patient investors, though tactical entry points around ₹480-500 would offer better risk-reward.
Note- ROCE= (EBIT - Other income)/(Capital Employed - Cash - Current Investments)
⚠️ Investment Disclaimer
This article is for educational and informational purposes only and should not be construed as financial advice. Investors should conduct their own due diligence, consider their risk tolerance and investment objectives, and consult with a qualified financial advisor before making any investment decisions. Past performance does not guarantee future results. Stock market investments carry inherent risks including loss of principal.
